Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH

被引:178
作者
Taraboletti, Giulia
D'Ascenzo, Sandra
Giusti, Ilaria
Marchetti, Daniela
Borsotti, Patrizia
Millimaggi, Danilo
Giavazzi, Raffaella
Pavan, Antonio
Dolo, Vincenza
机构
[1] Univ Aquila, Dipartimento Med Sperimentale, I-67100 Laquila, Italy
[2] Mario Negri Inst Pharmacol Res, Dept Oncol, I-24100 Bergamo, Italy
来源
NEOPLASIA | 2006年 / 8卷 / 02期
关键词
shed membrane vesicles; VEGF; tumor angiogenesis; pH; ovarian cancer;
D O I
10.1593/neo.05583
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor angiogenesis is regulated by a dynamic crosstalk between tumor cells and the host microenvironment. Because membrane vesicles shed by tumor cells are known to mediate several tumor - host interactions, we determined whether vesicles might also stimulate angiogenesis. Vesicles shed by human ovarian carcinoma cell lines CABAI and A2780 stimulated the motility and invasiveness of endothelial cells in vitro. Enzyme-linked immunosorbent assay and Western blot analysis revealed relevant amounts of vascular endothelial growth factor (VEGF) and the two matrix metalloproteinases MMP-2 and MMP-9, but not fibroblast growth factor-2, contained in shed vesicles. An A2780 cell derived clone transfected to overexpress VEGF shed the same amount of vesicles as did a control clone, but contained significantly more VEGF within the vesicles. Despite a greater amount of VEGF in vesicles of the overexpressing clone, vesicles of both clones stimulated endothelial cell motility to comparable levels, suggesting that VEGF was stored within the vesicle and was unavailable. Only following vesicle burst induced by acidic pH (a characteristic of the tumormicroenvironment) was VEGF released, leading to significantly higher stimulation of cell motility. Thus, tumor-shed membrane vesicles carry VEGF and release it in a bioactive form in conditions typical of the tumor microenvironment.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 37 条
[1]  
Abrahams VM, 2003, CANCER RES, V63, P5573
[2]  
Albanese J, 1998, BLOOD, V91, P3862
[3]   Malignant effusions and immunogenic tumour-derived exosomes [J].
Andre, F ;
Schartz, NEC ;
Movassagh, M ;
Flament, C ;
Pautier, P ;
Morice, P ;
Pomel, C ;
Lhomme, C ;
Escudier, B ;
Le Chevalier, T ;
Tursz, T ;
Amigorena, S ;
Raposo, G ;
Angevin, E ;
Zitvogel, L .
LANCET, 2002, 360 (9329) :295-305
[4]   Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines [J].
Angelucci, A ;
D'Ascenzo, S ;
Festuccia, C ;
Gravina, GL ;
Bologna, M ;
Dolo, V ;
Pavan, A .
CLINICAL & EXPERIMENTAL METASTASIS, 2000, 18 (02) :163-170
[5]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[6]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[7]  
Dolo V, 1997, ONCOL RES, V9, P129
[8]  
Dolo V, 1998, CANCER RES, V58, P4468
[9]  
DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173
[10]   Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro [J].
Dolo, V ;
D'Ascenzo, S ;
Violini, S ;
Pompucci, L ;
Festuccia, C ;
Ginestra, A ;
Vittorelli, ML ;
Canevari, S ;
Pavan, A .
CLINICAL & EXPERIMENTAL METASTASIS, 1999, 17 (02) :131-140